Drug Search Results
More Filters [+]

Neucardin

Alternative Names: neucardin, rhnrg-1
Latest Update: 2024-02-01
Latest Update Note: Clinical Trial Update

Product Description

Recombinant human neuregulin-1 (Neucardin®), developed by Zensun, is a novel genetically engineered biologic used in the treatment of mild and moderate chronic heart failure (CHF). The advantage of Neucardin® is that it can specifically target the cardiac muscle cell, repair the cell structure and improve function during heart contraction and relaxation, thereby improving cardiac function and reversing pathological ventricular remodeling,and significantly reducing death rate and readmission rate while improving the quality of life. (Sourced from: http://www.zensunus.com/product/center?id=19)

Mechanisms of Action: ERBB2 Binder

Novel Mechanism: Yes

Modality: Coagulation Factor

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Zensun
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Neucardin

Countries in Clinic: China

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Heart Failure, Chronic|Heart Failure, Systolic|Heart Murmurs|Systolic Murmurs

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ZS-01-306

P3

Recruiting

Heart Failure, Chronic

2026-02-01

54%

ZS-01-308B

P3

Recruiting

Heart Failure, Systolic|Systolic Murmurs|Heart Failure, Chronic|Heart Murmurs

2024-06-01

54%

ZS-01-308B

P3

Recruiting

Heart Failure, Systolic|Systolic Murmurs|Heart Failure, Chronic|Heart Murmurs

2024-06-01

54%

Recent News Events